TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28853975

Group type: EXPERIMENTAL
Intervention: website educational program only (n = 281)
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: website plus face to face lesson (n = 302)
Number of subjects: 917

Group type: COMPARATOR
Intervention: no intervention (n = 334)
Number of subjects: 917
Study: 27461787

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (4.0 mL buccal infiltration)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine (4.0 mL buccal infiltration)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 100
Study: 25361785

Group type: EXPERIMENTAL
Intervention: Cognitive training group (REHACOP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (occupational activities)
Number of subjects: 42
Study: 22549509

Group type: EXPERIMENTAL
Intervention: 930 mg/d choline intake
Number of subjects: 2

Group type: COMPARATOR
Intervention: 480 mg/d choline intake
Number of subjects: 2
Study: 20386478

Group type: EXPERIMENTAL
Intervention: Vibration training (VG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 31
Study: 17683643

Group type: EXPERIMENTAL
Intervention: Litebook LED treatment device (1,350 lux white light, spectral peaks at 464 nm and 564 nm) for 30 minutes a day upon awakening and prior to 8 A.M.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inactivated negative ion generator (control) for 30 minutes a day upon awakening and prior to 8 A.M.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Litebook LED treatment device
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inactivated negative ion generator (control)
Number of subjects: 26
Study: 16295262

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11926786

Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil plus inhaled iloprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 12.5 mg of sildenafil plus inhaled iloprost
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Iloprost alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 12.5 mg of sildenafil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil plus iloprost
Number of subjects: 30
Study: 9788422

Group type: EXPERIMENTAL
Intervention: 7 Gy preoperative irradiation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NSAID (Voltaren resinat 2 x 75 mg/day for 2 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Historical control group (no prophylactic therapy)
Number of subjects: 100
Study: 7649965

Group type: EXPERIMENTAL
Intervention: Involvement in drug research
Number of subjects: 63
Study: 2758840

Group type: EXPERIMENTAL
Intervention: Minilaparotomy and Yoon ring
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Laparoscopy and Yoon ring
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Minilaparotomy and Pomeroy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 91
Study: 1159592

Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exchange transfusion
Number of subjects: 0
Study: 31490864

Group type: EXPERIMENTAL
Intervention: Didactic teaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncontextual active learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no CRM education)
Number of subjects: 0
Study: 29330975

Group type: EXPERIMENTAL
Intervention: Desarda technique
Number of subjects: 186

Group type: COMPARATOR
Intervention: Darning technique
Number of subjects: 186
Study: 26122922

Group type: EXPERIMENTAL
Intervention: Consent to extended follow-up (10 years)
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Symptomatic status at baseline
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Smoking status at follow-up
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Hypertension status at follow-up
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Dyslipidemia status at follow-up
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Mean number of years in study at time of consent
Number of subjects: 1921

Group type: COMPARATOR
Intervention: Site enrollment size
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Odds of consenting based on age
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Odds of consenting based on symptomatic status
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Odds of consenting based on smoking status
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Odds of consenting based on duration in study
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Odds of consenting based on site enrollment size
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Odds of consenting based on dyslipidemia status
Number of subjects: 1921
Study: 23708162

Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 8795

Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 8795

Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 8795

Group type: COMPARATOR
Intervention: Normal
Number of subjects: 8795
Study: 22340054

Group type: EXPERIMENTAL
Intervention: LCAF + C group (late accelerated hyperfractionated radiotherapy combined with capecitabine)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: LCAF group (late accelerated hyperfractionated conformal radiotherapy)
Number of subjects: 168

Group type: COMPARATOR
Intervention: CF group (radiotherapy alone)
Number of subjects: 168
Study: 19930729

Group type: EXPERIMENTAL
Intervention: Communication techniques intervention
Number of subjects: 0
Study: 16510747

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary-vein ablation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (amiodarone and two cardioversions)
Number of subjects: 146
Study: 15228261

Group type: EXPERIMENTAL
Intervention: 10 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24
Study: 10528416

Group type: EXPERIMENTAL
Intervention: Suction pump
Number of subjects: 60

Group type: COMPARATOR
Intervention: Redon bottle
Number of subjects: 60
Study: 9074719

Group type: EXPERIMENTAL
Intervention: Heparin (1,250 IU x 2/SC/day for 30 days)
Number of subjects: 20
Study: 1680616

Group type: COMPARATOR
Intervention: Control group (no adrenergic blockade)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade with propranolol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blockade with phentolamine
Number of subjects: 18
Study: 6350097

Group type: EXPERIMENTAL
Intervention: Cimetidine, 1200 mg daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Antacid (Mylanta II, 7 oz daily)
Number of subjects: 138
Study: 30822490

Group type: EXPERIMENTAL
Intervention: Immediate periodontal treatment (full‐mouth non‐surgical scaling and root planing, systemic antibiotics, and oral hygiene instructions)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Delayed periodontal treatment (full‐mouth non‐surgical scaling and root planing, systemic antibiotics, and oral hygiene instructions)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Immediate periodontal treatment
Number of subjects: 22
Study: 28141666

Group type: EXPERIMENTAL
Intervention: Women with a history of breast cancer
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Unhealthy lifestyle behaviors
Number of subjects: 969

Group type: COMPARATOR
Intervention: Women without a history of breast cancer
Number of subjects: 969
Study: 27267255

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR) measured by transthoracic Doppler echocardiography
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR)
Number of subjects: 86
Study: 23965751

Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery (GKRS)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Repeated transsphenoidal adenomectomy (TSA)
Number of subjects: 52
Study: 22442079

Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with paired associative stimulation (PAS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patches combined with paired associative stimulation (PAS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 12
Study: 19383242

Group type: EXPERIMENTAL
Intervention: Enteric-coated diclofenac 50 mg, administered orally three times daily for 2 weeks prior to surgery
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg, administered orally three times daily for 2 weeks prior to surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo, administered orally three times daily for 2 weeks prior to surgery
Number of subjects: 51
Study: 17440419

Group type: EXPERIMENTAL
Intervention: HFO-TGI (combined high-frequency oscillation and tracheal gas insufflation)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HFO-TGI
Number of subjects: 14

Group type: COMPARATOR
Intervention: HFO
Number of subjects: 14
Study: 15852464

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 12411832

Group type: EXPERIMENTAL
Intervention: C‐beta‐CIT‐FE PET scans with statistical parametric mapping (SPM) analysis
Number of subjects: 16

Group type: COMPARATOR
Intervention: C‐beta‐CIT‐FE PET scans
Number of subjects: 16
Study: 9573535

Group type: EXPERIMENTAL
Intervention: Lowest tertile (UProt < 1.9 g/24 hr)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Middle tertile (UProt 2.0 to 3.8 g/24 hr)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Highest tertile (UProt 3.9 to 18.8 g/24 hr)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Patients with highest proteinuria and blood pressure
Number of subjects: 352
Study: 8159037

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 803

Group type: COMPARATOR
Intervention: Aspirin 300 mg thrice daily plus dipyridamole 75 mg thrice daily
Number of subjects: 803
Study: 3121710

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA) 80 mg over 3 h
Number of subjects: 290

Group type: COMPARATOR
Intervention: Streptokinase 1.5 million units over 1 h
Number of subjects: 290
Study: 30901755

Group type: EXPERIMENTAL
Intervention: Structured postoperative rehabilitation (SPT)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard postoperative approach (SA)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Both groups (SPT and SA)
Number of subjects: 202
Study: 27564924

Group type: EXPERIMENTAL
Intervention: Bilingual/bicultural lay health educator (LHE) education over 3 months
Number of subjects: 329

Group type: COMPARATOR
Intervention: Education regarding nutrition and physical activity delivered by a health educator
Number of subjects: 329
Study: 26343601

Group type: EXPERIMENTAL
Intervention: Blonanserin (8-24 mg/day)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 261
Study: 24302188

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray (FNS) with amoxicillin, one puff twice daily for 14 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amoxicillin 80 to 100 mg/kg/day for 14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray (FNS) with amoxicillin
Number of subjects: 100
Study: 21459951

Group type: EXPERIMENTAL
Intervention: Specialized rheumatology nurse (SRN)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Rheumatologist-led diagnostic consult (usual care, UC)
Number of subjects: 193
Study: 19478464

Group type: EXPERIMENTAL
Intervention: Hepcidin-20
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hepcidin-25
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hepcidin-20 and Hepcidin-25
Number of subjects: 12
Study: 17492413

Group type: EXPERIMENTAL
Intervention: Transurethral resection followed by early intravesical application of a chemotherapeutic agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ-sparing treatment due to combined therapeutic concepts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents
Number of subjects: 0
Study: 15536108

Group type: EXPERIMENTAL
Intervention: Amlodipine, 10 mg
Number of subjects: 1991

Group type: EXPERIMENTAL
Intervention: Enalapril, 20 mg
Number of subjects: 1991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1991

Group type: COMPARATOR
Intervention: Amlodipine vs Placebo
Number of subjects: 1991

Group type: EXPERIMENTAL
Intervention: Enalapril vs Amlodipine
Number of subjects: 1991

Group type: COMPARATOR
Intervention: IVUS Atherosclerosis Progression
Number of subjects: 1991
Study: 11327189

Group type: EXPERIMENTAL
Intervention: Normative feedback intervention pamphlet
Number of subjects: 697

Group type: COMPARATOR
Intervention: Control group (no normative feedback)
Number of subjects: 697
Study: 9216528

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.05% gel
Number of subjects: 318

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 318
Study: 7967692

Group type: EXPERIMENTAL
Intervention: Needling at empirical point Shengen
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (38 cases)
Number of subjects: 101
Study: 3118453

Group type: EXPERIMENTAL
Intervention: Oral phenoxymethylpenicillin 2 g every 8 h, reduced to 1 g every 8 h after normalization of temperature.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Intravenous benzylpenicillin 3 g every 8 h, reduced to oral phenoxymethylpenicillin 1 g every 8 h after normalization of temperature.
Number of subjects: 69
Study: 2746447

Group type: EXPERIMENTAL
Intervention: 3% monohydrogen‐monopotassium oxalate (MO)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 30% dipotassium oxalate (DO) followed by 3% MO
Number of subjects: 17

Group type: COMPARATOR
Intervention: Distilled water followed by 30% DO
Number of subjects: 17

Group type: COMPARATOR
Intervention: Distilled water followed by 3% MO
Number of subjects: 17

Group type: COMPARATOR
Intervention: Distilled water only
Number of subjects: 17
Study: 31504461

Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT; sub- and supragingival scaling/chlorhexidine; n=50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control periodontal treatment (CPT; supragingival scaling; n=51)
Number of subjects: 101
Study: 27533954

Group type: EXPERIMENTAL
Intervention: Low blood pressure variability (BPV < median)
Number of subjects: 261

Group type: COMPARATOR
Intervention: High blood pressure variability (BPV ≥ median)
Number of subjects: 261
Study: 25995537

Group type: EXPERIMENTAL
Intervention: Swiss ball exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mat exercises
Number of subjects: 20
Study: 23430159

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 20947211

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 18797408

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 17214926

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 14758306

Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM training
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Train-the-trainer classroom instruction
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 11329461

Group type: EXPERIMENTAL
Intervention: Detection of IgG bands of 25, 22, and/or 69 kDa
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CDC stage C
Number of subjects: 152

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 152
Study: 9447532

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 203

Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 203
Study: 7960981

Group type: EXPERIMENTAL
Intervention: Elective irradiation after wide local excision of lesions > or = 1.5 mm thick, or Clark's level IV‐V (n = 79)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adjunctive irradiation after excision of primary lesions plus limited neck dissection (n = 32)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Irradiation after neck dissection for nodal relapse (n = 63)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Overall group (all patients)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adjunctive radiotherapy
Number of subjects: 174
Study: 3232904

Group type: EXPERIMENTAL
Intervention: Lactose absorbers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study: 31543353

Group type: EXPERIMENTAL
Intervention: HAPA-based multicomponent interventions
Number of subjects: 262

Group type: COMPARATOR
Intervention: Health education alone (Control)
Number of subjects: 262
Study: 28520955

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) + bupivacaine (10 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intrathecal ketamine (0.1 mg/kg) + bupivacaine (10 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.3 mg) + ketamine (0.1 mg/kg) + bupivacaine (10 mg)
Number of subjects: 90
Study: 27241157

Group type: EXPERIMENTAL
Intervention: Self-management education for 6 months
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 391
Study: 24655682

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cultural respect and recognition of worth and dignity
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Experiential similarities between researcher and participants
Number of subjects: 62
Study: 22014541

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW) for 12 weeks, followed by etanercept 50 mg once weekly (QW)
Number of subjects: 124

Group type: COMPARATOR
Intervention: SC placebo BIW for 12 weeks, followed by etanercept 50 mg BIW for 12 weeks
Number of subjects: 124
Study: 20197099

Group type: EXPERIMENTAL
Intervention: Post-learning negative emotion (watching a 3-min negative video clip)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-learning positive emotion (watching a 3-min positive video clip)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calm and relaxed condition (control group)
Number of subjects: 0
Study: 17389703

Group type: EXPERIMENTAL
Intervention: High-dose propylthiouracil (PTU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTU plus KI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTU plus sodium ipodate
Number of subjects: 0
Study: 16271575

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) for 60 minutes a day, 5 times a week for 4 weeks
Number of subjects: 5
Study: 12729940

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10639692

Group type: EXPERIMENTAL
Intervention: Four 3-g glucose tablets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Four matched placebo tablets
Number of subjects: 38
Study: 7488817

Group type: EXPERIMENTAL
Intervention: Prophylaxis with multiple low doses of porcine surfactant
Number of subjects: 256

Group type: COMPARATOR
Intervention: Rescue therapy
Number of subjects: 256
Study: 1935927

Group type: EXPERIMENTAL
Intervention: Propofol (bolus 1.5 mg kg‐1, infusion 9 mg kg‐1 h‐1 for 10 min thereafter 6 mg kg‐1 h‐1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Etomidate (bolus 0.10 mg kg‐1, infusion 3 mg kg‐1 h‐1 reduced to 0.6 mg kg‐1 h‐1)
Number of subjects: 21
Study: 7047681

Group type: EXPERIMENTAL
Intervention: ADW hepatitis B vaccine
Number of subjects: 110

Group type: COMPARATOR
Intervention: AYW hepatitis B vaccine
Number of subjects: 110
Study: 31331219

Group type: EXPERIMENTAL
Intervention: FFR
Number of subjects: 350

Group type: COMPARATOR
Intervention: OCT
Number of subjects: 350
Study: 29969826

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with tacrolimus (TAC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS) with tacrolimus (TAC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 115
Study: 26337521

Group type: EXPERIMENTAL
Intervention: Suprapubic tube (SPT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Urethral catheter (UC)
Number of subjects: 62
Study: 24501241

Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Golimumab (early and delayed groups)
Number of subjects: 41
Study: 22147616

Group type: EXPERIMENTAL
Intervention: I-123 mIBG SPECT
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Order subsets expectation maximization
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Planar H/M
Number of subjects: 1118
Study: 20850069

Group type: EXPERIMENTAL
Intervention: HIFV (high intakes of fruits and vegetables)
Number of subjects: 68

Group type: COMPARATOR
Intervention: LOFAT (restrictive messages to limit consumption of high-fat foods)
Number of subjects: 68